NEW YORK (GenomeWeb) – Through a newly announced partnership with Fabric Genomics, genetic testing company Diagnomics has developed an ACMG-59 report to help healthcare provider organizations understand pathogenic and likely pathogenic variants.
The ACMG-59 is a set of 59 genes that the American College of Medical Genetics and Genomics recommends that laboratories report secondary findings from when performing clinical exome and genome sequencing tests.
For this partnership, San Diego-based Diagnomics is using Fabric Genomics' Fabric Enterprise clinical decision support platform to generate insights for the variant report. The companies said that this collaboration will allow them to make personalized medicine and genomics-based preventive care more widely available.
"We have applied innovative strategies to make an expansive test panel both accessible and affordable for clinical use," Diagnomics CEO Byung-In Lee said in a statement.
Oakland, California-based Fabric Genomics, formerly known as Omicia, touts its capabilities for enabling scalable clinical genomic testing.